Cytokinetics gains on detailed omecamtiv mecarbil data
Cytokinetics Inc. (NASDAQ:CYTK) added $1.47 (14%) to $12.29 on Monday after the company and partner Amgen Inc. (NASDAQ:AMGN) announced the presentation of detailed data from the expansion portion of the Phase II COSMIC-HF trial of omecamtiv mecarbil to treat chronic heart failure. The cardiac myosin activator met its primary pharmacokinetics endpoint and, in patients receiving pharmacokinetic-based dose titration of the molecule, showed significant improvements in pre-specified secondary measures of cardiac function.
The expansion phase evaluated 448 patients who received either 25 mg of an oral formulation of omecamtiv mecarbil twice daily, 25 mg twice daily with an option to increase to 50 mg depending on plasma concentration of omecamtiv mecarbil after two weeks, or placebo. ...